This article was originally published in The Gray Sheet
Executive SummaryNovartis subsidiary Ciba Vision acquires an initial 10% equity stake in the ophthalmic product start-up. The move gives Ciba exclusive marketing and distribution rights to Medennium's PRL (phakic refractive lens), an intraocular lens designed for implantation into the posterior chamber of the eye to correct hyperopia and myopia. Phase II trials for the PRL are ongoing in the U.S., with Phase III studies slated to begin in early 2001, Ciba says. A CE mark is expected sometime in 2001
You may also be interested in...
The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.